Autologous dendritic cells loaded ex vivo with tumor neoantigens, then reinfused to prime a T-cell response.
Radboud University Medical Center is initiating a Phase I/II trial for preventive dendritic cell vaccination in Lynch Syndrome carriers. This represents a shift toward prophylactic neoantigen strategies, targeting individuals with germline MMR mutations before tumor development to assess safety and immunogenicity.
Beijing Tiantan Hospital completed a Phase I study evaluating autologous dendritic cells loaded with tumor neoantigen peptides alongside temozolomide in newly diagnosed glioblastoma. The trial focused on safety and preliminary efficacy, contributing data on DC-based vaccine platforms in this indication.
EurekAlert reports on how neoantigen dendritic cell vaccines are reshaping immunotherapy. This highlights the diversification of vaccine modalities, with dendritic cell-based approaches offering an alternative mechanism to mRNA/DNA vaccines for antigen presentation.
Fudan University is conducting a clinical study of a personalized self-dendritic cell (self-DC) vaccine targeting neoantigens for advanced solid tumors. The trial focuses on the application of autologous dendritic cells loaded with patient-specific neoantigens, representing a distinct delivery platform within the personalized vaccine landscape.
H. Lee Moffitt Cancer Center and Research Institute is recruiting for a Phase I pilot evaluating a personalized dendritic cell vaccine for high-risk triple-negative breast cancer (TNBC). The study utilizes whole exome sequencing of residual tumors post-neoadjuvant chemotherapy to assess safety, feasibility, and immunogenicity.
Jonsson Comprehensive Cancer Center is running a Phase I trial for a neoantigen-targeted peptide-pulsed dendritic cell (ppDC) vaccine in patients with H3 G34-mutant diffuse hemispheric glioma. The active, non-recruiting study focuses on identifying the best dose and safety profile of this patient-specific immunotherapy.
ZSky Biotech Inc is conducting a multicenter, randomized Phase II study of ZSNeo-DC1.1, a personalized dendritic cell vaccine, combined with temozolomide for newly diagnosed glioblastoma. The trial’s primary endpoint is progression-free survival (PFS) per RANO 2.0 criteria, with exploratory objectives assessing antigen-specific T-cell responses.
Changhai Hospital is testing YS247, a personalized neoantigen-pulsed dendritic cell vaccine, for metastatic castration-resistant prostate cancer. The Phase I study aims to determine safety and the maximum tolerated dose across three dose levels, while monitoring PSA levels and immune stimulation.
A comprehensive review in EuropePMC synthesizes the current state of neoantigen-based T cell vaccines, covering design strategies, therapeutic barriers, and clinical advances. The article examines mechanisms across mRNA, peptide, and dendritic cell platforms, highlighting synergies with checkpoint blockade and the challenges of immunosuppressive tumor microenvironments.